Cost-utility of a modality of "C" virus hepatitis treatment in patients that do not respond to interferon plus ribavirin in Mexico

被引：0
|
作者：
Nevarez-Sida, A [1 ]
Constantino-Casas, P [1 ]
Garcia-Contreras, F [1 ]
机构：
[1] Mexican Inst Social Secur, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2006年 / 9卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)64451-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A47 / A47
页数：1
相关论文
共 50 条
  • [21] Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C
    Guido, M
    De Franceschi, L
    Felder, M
    Zagni, I
    Capelli, P
    Corrocher, R
    Rugge, M
    Cavallini, G
    Fattovich, G
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 : 206 - 206
  • [22] PEGYLATED INTERFERON ALPHA PLUS RIBAVIRIN TREATMENT OF CHRONIC HEPATITIS C IN PSORIATIC PATIENTS
    Tomasiewicz, Krzysztof
    Modrzewska, Romana
    [J]. HEPATOLOGY, 2008, 48 (04) : 907A - 907A
  • [23] Interferon alone versus interferon plus ribavirin in the treatment of patients with acute hepatitis C: A pilot study
    Santantonio, T
    Sinisi, E
    Guastadisegni, A
    Palumbo, E
    Pastore, G
    [J]. JOURNAL OF HEPATOLOGY, 2002, 36 : 128 - 128
  • [24] Pegylated interferon and ribavirin treatment for hepatitis C virus infection
    Palumbo, Emilio
    [J]. THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2011, 2 (01) : 39 - 45
  • [25] Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
    Abbas, Zaigham
    Tayyab, Ghiasun Nabi
    Qureshi, Mustafa
    Memon, Mohammad Sadik
    Subhan, Amna
    Shakir, Tanzila
    Jafri, Wasim
    Hamid, Saeed
    [J]. HEPATITIS MONTHLY, 2013, 13 (12)
  • [26] Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C
    Zhao, S. -H.
    Chu, Y. -L.
    Cheng, D. -X.
    Waqar, A. B.
    Yu, Q.
    Yang, P. -H.
    Xue, X.
    Yang, H. -J.
    Liu, E. -Q.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (09) : 1334 - 1339
  • [27] COST-UTILITY ANALYSIS OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALPHA AND RIBAVIRIN IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC HEPATITIS C
    Lukac, M.
    Bielik, J.
    Holoman, J.
    Tomek, D.
    Suvadova, A.
    Foltanova, T.
    Foltan, V
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A330 - A330
  • [28] HAEMATOLOGICAL ADVERSE EFFECTS OF INTERFERON AND RIBAVIRIN TREATMENT IN PATIENTS WITH CHRONIC C VIRUS HEPATITIS
    Taisescu, Citto Iulian
    Iliescu, Gabriela
    Taisescu, Oana
    Predescu, Anca
    Andrei, Ana Marina
    Catalin, Bogdan
    Silosi, Cristian
    Biciusca, Viorel
    [J]. FARMACIA, 2015, 63 (03) : 465 - 469
  • [29] Comparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2
    Seo, Kayo
    Kim, Soo Ki
    Kim, Soo Ryang
    Ohtani, Aya
    Kobayashi, Mana
    Kato, Airi
    Morimoto, Eri
    Saijo, Yuka
    Kim, Ke Ih
    Imoto, Susumu
    Kim, Chi Wan
    Yano, Yoshihiko
    Kudo, Masatoshi
    Hayashi, Yoshitake
    [J]. DIGESTIVE DISEASES, 2017, 35 (06) : 541 - 547
  • [30] Interferon plus ribavirin for chronic hepatitis C HIV+ patients
    Soriano, V
    González, J
    Pérez-Olmeda, M
    García-Samaniego, J
    [J]. AIDS, 1998, 12 : S92 - S92
12345